Advertisement

Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 7120 | Ordered by Date (descending)
1 2 3 ... 70 71 72  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Eligo Bioscience–SEVERAL: investment, 202312 financing round Series B $30m led by Sanofi Ventures 2023-12-05
Exscientia–Open Philanthropy: grant, 202312– grant $2.3m for research in host interferon response as therapeutic approach for pandemic influenza 2023-12-05
IBA (BE)–Univ Kansas: proton therapy, 202312– colllab research using ConformalFLASH technology on ProteusONE system with KUMC 2023-12-05
Carmot Therapeutics–Roche: investment, 202312– acquisition $2.7b upfront + $400m milestones by Roche 2023-12-04
Freeline Therapeutics–Syncona: credit, 202311–202411 secured convertible loan note up to $15m with 12% interest + conversion price of $6.5/ADS 2023-11-22
Freeline Therapeutics–Syncona: investment, 202311– acquisition all remaining shares $6.5/ADS in going-private valuing entire issued capital at $28.3m 2023-11-22
Vivodyne–Bison Ventures: investment, 202311 seed financing round totalling $38m incl co-investor Bison Ventures 2023-11-22
Vivodyne–CS Ventures: investment, 202311 seed financing round totalling $38m incl co-investor CS Ventures 2023-11-22
Vivodyne–Kairos Ventures: investment, 202311 seed financing round totalling $38m incl co-investor Kairos Ventures 2023-11-22
Vivodyne–Khosla Ventures: investment, 202311 seed financing round totalling $38m incl lead investor Khosla Ventures 2023-11-22
Vivodyne–KKH Advisors: public relations, 202311 service existent by KKH Advisors 2023-11-22
Vivodyne–MBX Capital: investment, 202311 seed financing round totalling $38m incl co-investor MBX Capital 2023-11-22
Vivodyne–SEVERAL: investment, 202311 seed financing round $38m led by Khosla Ventures 2023-11-22
Caraway Therapeutics–Merck (US): investment, 202311– acquisition up to $610m by Merck SIGNED 2023-11-21
Evolva–Lallemand: investment, 202311– acquisitions of operations via 100% of Evolva AG for CHF20m + CHF10m milestones by Danstar Ferment AG 2023-11-21
Quotient Therapeutics–Flagship Pioneering: investment, 202311 Quotient Tx unveiled with initial $50m commitment from Flagship Pioneering 2023-11-21
Roche–Nvidia: AI-based drug r+d, 202311– collab strategic alliance multi-year of Genentech with Nvidia using Nvidia DGX Cloud + Nvidia BioNemo 2023-11-21
T-Therapeutics–SEVERAL: investment, 202311 financing round Series A Ł48m 2023-11-15
Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures 2023-11-14
VectorY–Insight Partners: investment, 202311 financing round Series A totalling €129m incl co-investor Insight Partners 2023-11-13
VectorY–Merck (US): investment, 202311 financing round Series A totalling €129m incl co-investor MRL Ventures Fund 2023-11-13
VectorY–SEVERAL: investment, 202311 financing round Series A €129m co-led by EQT Life Sciences + Forbion Growth Opportunities Fund 2023-11-13
ViaNautis Bio–4BIO Ventures: investment, 202311 financing round Series A totalling $25m incl co-lead investor 4BIO Capital 2023-11-13
ViaNautis Bio–BGF: investment, 202311 financing round Series A totalling $25m incl co-lead investor BGF 2023-11-13
ViaNautis Bio–Cystic Fibrosis Foundation: investment, 202311 financing round Series A totalling $25m incl co-investor Cystic Fibrosis Foundation 2023-11-13
ViaNautis Bio–Origin Capital: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Origin Capital 2023-11-13
ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures 2023-11-13
ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures 2023-11-13
Cromatic–SEVERAL: investment, 2023011 seed financing round $5.3m co-led by LifeX Ventures + AgFunder 2023-11-09
Kynexis–Forbion: investment, 202311 financing round Series A totalling €57m incl co-founding + lead investor Forbion 2023-11-07
Kynexis–SEVERAL: investment, 202311 financing round Series A €57m led by Forbion 2023-11-07
Kynexis–Sunstone Life Science: investment, 202311 financing round Series A totalling €57m incl co-investor Sunstone Life Science Ventures 2023-11-07
Kynexis–Ysios Capital: investment, 202311 financing round Series A totalling €57m incl co-founding + co-investor Ysios Capital 2023-11-07
Valanx Biotech–SEVERAL: investment, 202311 growth financing round €2.3m incl equity + public funding led by SkyGene 2023-11-07
Valanx Biotech–SOSV: investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor SOSV 2023-11-07
Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV 2023-11-02
Cambrium–Essential Capital: investment, 202311 seed financing round totalling €8m incl lead investor Essential Capital 2023-11-01
Cambrium–Hof Capital: investment, 202311 seed financing round totalling €8m incl co-investor Hof Capital 2023-11-01
Cambrium–SEVERAL: investment, 202311 seed financing round €8m led by Essential Capital 2023-11-01
Cambrium–SNR: investment, 202311 seed financing round totalling €8m incl co-investor SNR 2023-11-01
Cambrium–Valor Equity Partners: investment, 202311 seed financing round totalling €8m incl co-investor Valor Equity Partners 2023-11-01
Kynexis–Mitsubish Chemical: KAT-II inhibitor, 202311c– license excl ww rights to develop + commercialize KYN-5356 from MTPC 2023-11-01
LimFlow–Inari Medical: investment, 202311– acquisition $250m cash upfront at closing + $165m by Inari Medical 2023-11-01
Carlyle–SEVERAL: investment, 202310 final closing $356m of Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) 2023-10-30
MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets 2023-10-30
Moderna–Caris Life Sciences: genomic profiling, 202310– strategic collab multi-year clinico-genomics data for mRNA-based precision cancer drugs 2023-10-24
Merck (US)–Daiichi Sankyo: antibody-drug conjugates, 202310– collab developm + commerc 3 DXd ADCs ww excl JP $4b upfront + $18b milestones 2023-10-19
Olink–Thermo Fisher: investment, 202310– acquisition cash tender offer $3.1b at $26/share by Thermo Fisher 2023-10-17
Servier–Owkin: AI-based drug discovery, 202310– collab using AI for RnD of precision therapeutics for cancer + other indications 2023-10-17
VedaBio–SEVERAL: investment, 202310 initial funding >$40m led by OMX Ventures at announced launch 2023-10-17
AOA Dx–SEVERAL: investment, 202310 financing round $17m led by Good Grwoth Capital bringing total raised to $24m 2023-10-12
BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC 2023-10-12
Agomab Therapeutics–Canaan Partners: investment, 202310 financing round Series C totalling $100m incl new + co-investor Canaan 2023-10-10
Agomab Therapeutics–EQT: investment, 202310 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences 2023-10-10
Agomab Therapeutics–Fidelity: investment, 202310 financing round Series C totalling $100m incl lead investor Fidelity Mgt and Research 2023-10-10
Agomab Therapeutics–KKR: investment, 202310 financing round Series C totalling $100m incl new + co-investor Dawn Biopharma 2023-10-10
Agomab Therapeutics–OTHER: investment, 202310 financing round Series C totalling $100m incl existing investors 2023-10-10
Agomab Therapeutics–SEVERAL: investment, 202310 financing round Series C $100m (€94.9m) led by Fidelity Mgt and Research Company 2023-10-10
Mana.bio–SEVERAL: investment, 202310 seed financing round $19.5m co-led by Andreessen Horowitz B+H+ Base4 Capital + NFX + LionBird + Technion 2023-10-10
AstronauTx–SEVERAL: investment, 202310 financing round Series A ťŁ48m led by Novartis Venture Fund 2023-10-09
LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund 2023-10-09
Mirati–BMS: investment, 202310– acquisition $4.8b in cash (incl $1.1b cash of Mirati) at $58/share plus $1b CVR at $12/CVR 2023-10-08
Precede Biosciences–5AM Ventures: investment, <202310 seed financing round incl existing co-founding investor 5AM Ventures 2023-10-05
Precede Biosciences–5AM Ventures: investment, <=202310 financing round Series A incl existing + co-lead investor 5AM Ventures 2023-10-05
Precede Biosciences–BMS: investment, <=202310 financing round Series A incl new + co-investor BMS 2023-10-05
Precede Biosciences–Harvard Univ: investment, <202310 seed financing round incl investor Binney Street Capital 2023-10-05
Precede Biosciences–Illumina: investment, <=202310 financing round Series A incl new + co-investor Illumina Ventures 2023-10-05
Precede Biosciences–Lilly Asia Ventures: investment, <=202310 financing round Series A incl new + co-lead investor Lilly Asia Ventures 2023-10-05
Precede Biosciences–Osage Partners: investment, <=202310 financing round Series A incl new + co-investor Osave University Partners 2023-10-05
Precede Biosciences–Qatar (govt): investment, <=202310 financing round Series A incl new + co-investor Qatar Investment Authority 2023-10-05
Precede Biosciences–SEVERAL: investment, <202310 seed financing round with co-founder 5AM Ventures + Binney Street Capital 2023-10-05
Precede Biosciences–SEVERAL: investment, <=202310 financing round Series A announced when Precede emerged from stealth with $57m in backing 2023-10-05
MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker 2023-10-04
Point Biopharma–Lilly: investment, 202310– cash tender offer $1.4b by Lilly at $12.5/share 2023-10-03
Mogrify–SEVERAL: investment, 202310 financing round Series A extension $10m bringing total Series A to $46m led by Astellas VM & Parkwalk Advisors 2023-10-02
MetrioPharm–SEVERAL: investment, 202310c financing round Series D 1st closing CHF18m 2023-10-01
Abivax–SEVERAL: investment, 202309–202310 European private placement €17.9m with 1.6m new ordinary shares at €10.99/share 2023-09-29
Abivax–SEVERAL: investment, 202309–202310 US IPO $217m with 18.7m ADSs (new ordinary shares) at $11.6/ADS at Nasdaq Global Market 2023-09-29
Laverock Therapeutics–Lilly: investment, 202309 seed financing round totalling Ł13.5m incl co-investor Eli Lilly 2023-09-28
Laverock Therapeutics–Mattioli Woods: investment, 202309 seed financing round totalling Ł13.5m incl co-investor Maven Capital Partners 2023-09-28
Laverock Therapeutics–Mercia: investment, 202309 seed financing round totalling Ł13.5m incl co-investor Mercia Ventures 2023-09-28
Laverock Therapeutics–SEVERAL: investment, 202309 seed financing round expansion to Ł13.5m led by Calculus Capital 2023-09-28
BioProtect–MVM: investment, 202309 financing round totalling $28m incl new + lead investor MVM Partners 2023-09-27
BioProtect–SEVERAL: investment, 202309 financing round $28m led by MVM Partners 2023-09-27
Co.faktor–Cytel: investment, 202309 acquisition of Co.faktor GmbH by Cytel Inc 2023-09-26
Cytel–BioStrata: public relations, 202309 service existent by BioStrata 2023-09-26
Novo Group–Valo Health: AI-based drug discovery, 202309– collab + license up to $2.7b using Opal Computation Platform in cardiometabolic disease 2023-09-25
Pepceuticals–Biosynth: investment, 202309 acquisition of Pepceuticals Ltd by Biosynth 2023-09-25
Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202309–203309 supply 10y >$100m of nca lutetium-177 to Point Biopharma 2023-09-25
BenevolentAI–FTI Consulting: public relations, 202309 service existent by FTI Consulting 2023-09-20
Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront 2023-09-20
Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties 2023-09-20
Broken String Biosciences–Illumina: investment, 202309 financing round Series A totalling $15m incl new + co-lead investor Illumina Ventures 2023-09-18
Broken String Biosciences–SEVERAL: investment, 202309 financing round Series A $15m co-led by Illumina Ventures + Mérieux Equity Partners 2023-09-18
Broken String Biosciences–Tencent: investment, 202309 financing round Series A totalling $15m incl existing + co-investor Tencent 2023-09-18
Scinai Immunotherapeutics–SEVERAL: investment, 202309 registered direct offering $1.33m with 1.15m ADSs at $1.16/ADS 2023-09-15
RayzeBio–PeptiDream: investment, 202309 DIVESTMENT via IPO ./.$20.9m with 1.163m shares sold by PeptiDream at $18/share resulting 2% shareholding 2023-09-14
RayzeBio–SEVERAL: investment, 202309 IPO $336.7m with 16.1m+2.6m new shares at $18/share (excl 1.163m shares sold by PeptiDream) 2023-09-14
BioLamina–Lauxera: investment, 202309 investment €17m by Lauxera Growth I fund 2023-09-12
Consilium–ICR: investment, 202309 acquisition of Consilium Strategic Communications by ICR 2023-09-12
1 2 3 ... 70 71 72  next pagenext page



Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture EBD Group Biotech Showcase 2024 San Francisco 650x300px

» top